Latest market price
37.16
-1.35-3.51%
OverviewShort InterestFilings
CSTLQT77Castle Biosciences, Inc.·NASDAQ
37.16-3.51%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
OPK+0.00%$1.66PSNL-0.69%$15.82WGS-2.76%$69.06MYGN-4.80%$6.35FLGT-4.89%$20.62VCYT-4.14%$50.01CDNA+22.22%$87.41SHC-2.94%$18.15
Snapshot
Index—P/E—EPS (ttm)-0.66Insider Own2.43%Shs Outstand30.55MPerf Week12.33%
Market Cap1.14BForward P/E—EPS next Y-0.93Insider Trans-44.18%Shs Float27.18MPerf Month5.39%
Enterprise Value903.22MPEG—EPS next Q-0.35Short Float7.42%Perf Quarter22.28%
Income-20.00MP/S3.17EPS this Y—Short Ratio4.96Perf Half Y49.78%
Sales358.00MP/B2.42EPS next Y—ROA-3.46%Short Interest2.02MPerf YTD-4.47%
Book/sh15.38P/C4.25EPS next 5Y—ROE-4.15%52W High44.28 -16.08%Perf Year56.53%
Cash/sh8.74P/FCF—EPS past 3/5Y—ROIC-6.31%52W Low17.72 109.71%Perf 3Y193.52%
Dividend Est.—EV/EBITDA—Sales past 3/5Y35.92% 40.42%Gross Margin77.26%Volatility5.44% 5.00%Perf 5Y-40.76%
Dividend TTM—EV/Sales2.52EPS Y/Y TTM—Oper. Margin-8.99%ATR (14)1.70Perf 10Y—
Dividend Ex-Date—Quick Ratio5.85Sales Y/Y TTM3.47%Profit Margin-5.43%RSI (14)60.87Recom2.00
Dividend Gr. 3/5Y—Current Ratio6.04EPS Q/Q-146.67%SMA209.01%Beta1.02Target Price38.75
Payout0.00%Debt/Eq0.07Sales Q/Q20.93%SMA508.60%Rel Volume0.90Prev Close38.51
Employees1,002LT Debt/Eq0.07EarningsNov 05SMA20030.26%Avg Volume370.65KPrice37.16
IPO DateJul 25, 2019Option/ShortYes / YesEPS/Sales Surpr.82.80% 20.07%Net Debt/EBITDA—Volume334,258Change-3.51%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-03-26ReiteratedBTIGBuy$50 → $44
Jul-31-26ReiteratedRobert W. Baird$43 → $36
Jun-24-26InitiatedRoth CapitalBuy$40
May-29-26ReiteratedKeyBancOverweight$50 → $35
Apr-20-26ReiteratedCanaccord GenuityBuy$50 → $40
Jan-29-26ReiteratedKeyBancOverweight$36 → $50
Jan-26-26ReiteratedGuggenheimBuy$43 → $47
Jan-12-26ReiteratedLake StreetBuy$52
Jan-05-26ReiteratedGuggenheimBuy$30 → $43
Dec-22-25ReiteratedCanaccord GenuityBuy$42 → $50
Latest News· Times ET
Oct-28-26
Oct-28-2607:00AM
Castle Biosciences to Participate in Upcoming Investor Conferencesprnewswire.com
Oct-15-26
Oct-15-2607:00AM
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026prnewswire.com
Oct-12-26
Oct-12-2607:59PM
Castle Biosciences Inc (CSTL) Shares Fall 4.8% -- What GF Score of 80 Tells Investorsgurufocus.com
04:30PM
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagusprnewswire.com
Oct-09-26
Oct-09-2601:15AM
New Melanoma Study Backing DecisionDx-Melanoma Could Be A Game Changer For Castle Biosciences (CSTL)Yahoo
Oct-06-26
Oct-06-2610:40AM
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 6.1% Following Insider Sellingdefenseworld.net
Oct-02-26
Oct-02-2606:10AM
Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,034 Shares of Stockdefenseworld.net
Sep-30-26
Sep-30-2604:30PM
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Managementprnewswire.com
Sep-28-26
Sep-28-2607:00AM
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagusprnewswire.com
Sep-24-26
Sep-24-2604:30PM
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™prnewswire.com
Sep-22-26
Sep-22-2607:00AM
Castle Biosciences to Open New Laboratory Facility in Scottsdaleprnewswire.com
03:13AM
Castle Biosciences Announces Opening Of New Laboratory And Office Facility In Scottsdale, ArizonaBenzinga
Sep-15-26
Sep-15-2607:00AM
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagusprnewswire.com
Sep-09-26
Sep-09-2604:30PM
JAAD Publication Shows Improved Performance of DecisionDx®-SCCprnewswire.com
Sep-08-26
Sep-08-2609:30AM
SciBase receives additional order from Castle Biosciences, advancing the collaborationprnewswire.com
Company

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue358344332220—————
Cost of Goods Sold Incl. D&A82716045—————
Gross Profit276273272175—————
Selling, General and Administrative Excl. Other244229200180—————
Research and Development56525254—————
Other Operating Expense935119—————
Operating Income-32-439-68—————
Interest Expense0010—————
Unusual Expense
—————————
Non-Operating Income (Expense)13131311—————
Net Income Before Taxes-19-3022-57—————
Income Taxes0-530—————
Consolidated Net Income-20-2418-57—————
Net Income From Continuing Operations-20-2418-57—————
Net Income-20-2418-57—————
EPS (Recurring)-0.66-0.830.66-2.14—————
EPS (Basic, Before Extraordinaries)-0.66-0.830.66-2.14—————
EPS (Diluted)-0.66-0.830.62-2.14—————
EBITDA-31138-45—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——42.98——————
Price To Sales Ratio3.113.282.252.65—————
Gross Margin77.0979.3681.9379.55—————
Operating Margin-8.94-12.502.71-30.91—————
Net Margin-5.59-6.985.42-25.91—————
Shares Outstanding30292827—————
Market Capitalization1,1151,128746583—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$46.77$38.68$30.59$22.51$14.42● Close Price0.00M1.22M2.43M3.65M4.86MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Juvenal Tobin WChief Commercial OfficerOct 28 '26Sale36.426,578239,59138,853Oct 30
Juvenal Tobin WChief Commercial OfficerOct 26 '26Sale33.083,288108,76745,431Oct 28
MAETZOLD DEREK JPres. & Chief Exec. OfficerOct 19 '26Sale31.9114,496462,5674,114Oct 21
Juvenal Tobin WChief Commercial OfficerOct 12 '26Sale33.643,288110,60848,719Oct 14
MAETZOLD DEREK JPres. & Chief Exec. OfficerOct 05 '26Sale35.5714,496515,5646,832Oct 07
MAETZOLD DEREK JPres. & Chief Exec. OfficerOct 05 '26Option Exercise2.398,16519,51429,644Oct 07
Oelschlager Kristen MChief Operating OfficerOct 01 '26Option Exercise3.384,15314,03717,509Oct 05
Oelschlager Kristen MChief Operating OfficerOct 01 '26Sale35.954,153149,31713,356Oct 05
Juvenal Tobin WChief Commercial OfficerSep 30 '26Sale34.201,03435,36352,007Oct 01
Juvenal Tobin WChief Commercial OfficerSep 29 '26Sale35.505,543196,76553,041Oct 01
MAETZOLD DEREK JPres. & Chief Exec. OfficerSep 21 '26Option Exercise2.398,58020,50630,059Sep 23
MAETZOLD DEREK JPres. & Chief Exec. OfficerSep 21 '26Sale35.3314,496512,2029,550Sep 23
Juvenal Tobin WChief Commercial OfficerSep 15 '26Sale35.143,294115,75858,584Sep 16
Juvenal Tobin WChief Commercial OfficerSep 14 '26Sale32.323,306106,86361,878Sep 16
MAETZOLD DEREK JPres. & Chief Exec. OfficerSep 11 '26Sale32.0214,518464,87012,268Sep 15
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.